Patrick Zweidler-McKay

Patrick Zweidler-McKay

Company: ImmunoGen

Job title: Senior Medical Director


Looking into IMGN632 Development in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 5:00 pm

IMGN632, a novel anti-CD123 targeting ADC FDA Breakthrough Therapy Designation (BTD) granted in R/R BPDCN Results from the largest-to-date prospective group of uniformly treated patients with R/R BPDCNRead more

day: day 1 opps
day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.